Product Specification

Efficient IC Process and Anaerobic Solutions for Pharmaceutical Wastewater Treatment Projects in South Korea

South Korea has established itself as a global powerhouse in pharmaceutical manufacturing and biotechnology. With a robust infrastructure for R&D and large-scale production, the South Korean pharmaceutical industry is a key pillar of the national economy. However, this leadership comes with the responsibility of managing complex industrial effluents. As environmental regulations tighten, the demand for advanced Pharmaceutical Wastewater Treatment Projects has surged. Center Enamel, a premier global EPC contractor, provides high-efficiency Anaerobic Solutions, specifically the Internal Circulation (IC) process, to help South Korean enterprises achieve superior environmental performance.

South Korea’s Pharmaceutical Landscape and Environmental Policy

South Korea is home to some of the world's leading biopharmaceutical companies and a thriving network of traditional pharmaceutical manufacturers. To maintain its competitive edge while protecting its natural resources, the South Korean government has implemented stringent environmental policies. The "Water Environment Conservation Act" mandates strict standards for the discharge of industrial wastewater, focusing on the reduction of organic pollutants and hazardous substances.

For manufacturers operating in major clusters like Incheon (Songdo) or Osong, compliance is not just a regulatory requirement but a core component of Corporate Social Responsibility (CSR). The pressure to modernize aging treatment facilities or implement new, high-capacity systems makes specialized solutions like the IC process essential for maintaining operational continuity and market reputation.

The Complexity of Pharmaceutical Wastewater

Pharmaceutical manufacturing generates wastewater that is significantly more difficult to treat than standard municipal sewage. While municipal waste typically comes from domestic activities (kitchens and bathrooms), industrial pharmaceutical effluent is defined by:

High Toxicity: Residues of antibiotics and active pharmaceutical ingredients (APIs) can inhibit the biological activity required for traditional wastewater treatment.

High Organic Loading: Production processes often result in extremely high levels of Chemical Oxygen Demand (COD), which require powerful anaerobic digestion to break down efficiently.

Chemical Variability: Frequent changes in production lines lead to fluctuating pH levels and chemical compositions, creating "shock loads" that can destabilize standard treatment plants.

Comprehensive Pharmaceutical Wastewater Treatment Flow

To address these challenges, Center Enamel delivers a scientifically structured treatment flow designed for maximum efficiency:

Pre-treatment: Utilizing physical screening and pH adjustment to stabilize the effluent before biological treatment.

Anaerobic Core: The most critical stage where IC or UASB reactors digest the heavy organic load and convert it into renewable biogas.

Aerobic Polishing: Secondary biological treatment to further reduce COD and remove nutrients.

Advanced Filtration: Using membranes or activated carbon to ensure the final water meets South Korea's strict discharge or reclamation standards.

Core Anaerobic Technologies: IC, UASB, CSTR, and USR

Center Enamel integrates diverse reactor technologies to optimize treatment performance:

IC (Internal Circulation) Reactor: A next-generation high-rate reactor that uses a two-stage anaerobic process. Its internal circulation mechanism allows it to handle much higher organic loads and provides exceptional stability against the chemical fluctuations common in pharmaceutical plants.

UASB (Upflow Anaerobic Sludge Blanket): A classic, energy-efficient solution that passes wastewater through a dense blanket of anaerobic sludge, perfect for high-strength liquid waste.

CSTR (Continuous Stirred Tank Reactor): Ideal for wastewater with high suspended solids (SS), using mechanical agitation to ensure complete digestion.

USR (Upflow Solids Reactor): Specifically designed for high-solid streams, ensuring organic particles are fully processed into biogas.

The Advantage of Glass-Fused-to-Steel (GFS) Tanks

Center Enamel’s EPC solutions utilize proprietary Glass-Fused-to-Steel (GFS) tanks as the primary containment vessels. These tanks offer several advantages over traditional concrete for the South Korean market:

Exceptional Corrosion Resistance: The glass-to-steel bond is impervious to aggressive chemicals and organic acids, ensuring the system remains leak-proof for over 30 years.

Rapid Modular Installation: Bolted assembly is significantly faster than concrete pouring, allowing for quick deployment even in congested industrial areas.

Design Flexibility: GFS tanks can be easily modified or expanded, providing the scalability needed to match a growing production facility.

Why Choose Center Enamel as Your EPC Partner?

As a global leader, Center Enamel provides a seamless, turnkey experience:

Customized Engineering: Our systems are precision-engineered to meet the specific effluent standards and chemical profiles of your site.

Proven Global Expertise: With successful projects in over 100 countries, we bring international engineering standards to South Korea’s industrial sector.

Full Lifecycle Support: We manage everything from initial design and GFS tank fabrication to automated control systems and commissioning.

Success Stories in Pharmaceutical Treatment

Case 1: Jiangsu Pharmaceutical Wastewater Treatment Project

Process: CSTR

Tank Dimensions:

φ10.7 × 16.8 m (H) — 2 Units

φ7.64 × 3.6 m (H) — 2 Units

φ5.35 × 3.6 m (H) — 4 Units

φ3.82 × 3.6 m (H) — 2 Units

Total Tank Volume: 3,748 m³

Completion Date: 2021

Case2: Zhejiang Pharmaceutical Plant Wastewater Treatment Project

Process: IC

Tank Dimensions: φ12.66 × 24 m (H) — 6 Units

Total Tank Volume: 18,114 m³

Completion Date: 2019

South Korea’s pharmaceutical industry demands advanced, reliable, and sustainable wastewater solutions. Center Enamel’s integration of the IC process and Glass-Fused-to-Steel technology provides manufacturers with a high-performance foundation for environmental compliance. By partnering with an experienced EPC contractor, South Korean companies can effectively manage toxic effluents while contributing to a greener industrial future and ensuring their long-term competitiveness in the global biopharmaceutical market.